Back to Directory
Ecnoglutide
Metabolic & Weight ManagementLong-acting GLP-1 agonist with unique structure being developed for type 2 diabetes.
Key Benefits
- ✓Glucose control
- ✓Weight loss
- ✓Weekly dosing
- ✓T2D treatment
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly
Typical Duration
Clinical trials
Detailed Protocol
Under development. Weekly subcutaneous injection in trials. Phase 3 trials ongoing.
About Ecnoglutide
Ecnoglutide (formerly HM15211) is a GLP-1 receptor agonist with a unique structure providing weekly dosing. Being developed for type 2 diabetes with clinical trials ongoing.
Research Notes
Phase 2 trials showed non-inferiority to semaglutide. Phase 3 program ongoing in China and globally. Another competitor in crowded GLP-1 market.
Potential Side Effects
- •Expected GLP-1 side effects
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.